Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
Want to see BRNS full AI Analyst Report?
BRNS Stock Chart & Stats
$0.76
>-$0.01(-0.43%)
At close: 4:00 PM EST
$0.76
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.51 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)124.73K
Market Cap
$28.06M
Enterprise Value-$28.12M
Total Cash (Recent Filing)$67.19M
Total Debt (Recent Filing)$11.01M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap-1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.96
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$7.00Price Target Upside821.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthModest debt levels materially lower refinancing and interest burdens for a cash-burning clinical-stage biotech. Low leverage preserves financing optionality and reduces near-term solvency pressure, enabling management to pursue trials, partnerships or deal execution without urgent debt constraints.
Reported Cash RunwayA reported $71.9M cash balance and an estimated runway into 2027 give the company a tangible buffer to reach upcoming clinical readouts and complete the proposed merger. This liquidity reduces immediate financing needs and supports execution of development milestones over the medium term.
Focused Pipeline And Clinical ProgressManagement’s strategic refocus on immune tolerance, advancement of VTP-1000 through Phase 1, and positive Phase 2 results for VTP-300 concentrate resources on higher-probability assets. A tighter, milestone-driven pipeline increases clarity and the potential for durable clinical value creation.
Bears Say
Revenue Collapse And VolatilityRevenue falling to zero and historical volatility indicate the company lacks a stable commercial base and depends on irregular and nonrecurring sources. This erodes operational predictability, increases reliance on external capital, and elevates execution risk if financing becomes constrained.
Persistent Negative Cash FlowConsistent negative operating and free cash flow reflect sustained cash burn tied to clinical development and restructuring. Ongoing deficits necessitate repeated external funding or strategic transactions, which can dilute equity and limit the company’s ability to invest in multiple programs simultaneously.
Merger Execution And Deal Complexity RiskMultiple amendments to a cross-border merger—changing exchange ratios and cash covenants—signal execution, timing and integration risk. Complex deal terms can delay strategic benefits, create ownership uncertainty, and force additional cash or dilutive actions if closing conditions or timelines slip.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.51 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $28.06M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 72 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Apr 30, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.14.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 8.514%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Stock 12 Month Forecast
Average Price Target
$7.00
▲(821.05% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
0.19%
Insiders
0.03% Mutual Funds
21.69% Other Institutional Investors
78.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---